Why microdosing Mounjaro is not licensed
Microdosing Mounjaro (tirzepatide) is not licensed in the UK because the medicine is approved only at specific doses and schedules that have been tested in clinical trials. Using smaller, non-standard doses over extended periods can affect dose accuracy, medicine stability, and treatment safety. Mounjaro pens are designed to deliver approved weekly doses and are not validated for prolonged microdosing use.
Once a Mounjaro pen is opened, it must be used within 30 days, regardless of how much medicine remains. Microdosing often leads to pens being used beyond this limit, which may reduce effectiveness or increase the risk of contamination. For these reasons, microdosing Mounjaro falls outside UK licensing and manufacturer guidance, and prescribing should always follow approved dosing schedules.
- Microdosing Mounjaro is not UK licensed.
- Pens expire 30 days after first use, even if medicine remains.
- Extended use can affect stability and dose accuracy.
- Pens are designed for approved weekly doses only.
- Licensed dosing is required for safety and effectiveness.
This text has been fact checked for accuracy by Sorin Romaniuc, Pharmacist at medino.